Literature DB >> 31122910

Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia.

Christine M McMahon1, Jonathan Canaani2, Bryan Rea3, Rachel L Sargent4, Julianne N Qualtieri5, Christopher D Watt5, Jennifer J D Morrissette5, Martin Carroll1,6, Alexander E Perl1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31122910      PMCID: PMC6538870          DOI: 10.1182/bloodadvances.2018029496

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


× No keyword cloud information.
  15 in total

1.  FLT3 Inhibitor-Associated Neutrophilic Dermatoses.

Authors:  Nisha Varadarajan; Andrea Boni; David E Elder; Adam Bagg; Robert Micheletti; Alexander E Perl; Misha Rosenbach
Journal:  JAMA Dermatol       Date:  2016-04       Impact factor: 10.282

2.  Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.

Authors:  Jorge Cortes; Alexander E Perl; Hartmut Döhner; Hagop Kantarjian; Giovanni Martinelli; Tibor Kovacsovics; Philippe Rousselot; Björn Steffen; Hervé Dombret; Elihu Estey; Stephen Strickland; Jessica K Altman; Claudia D Baldus; Alan Burnett; Alwin Krämer; Nigel Russell; Neil P Shah; Catherine C Smith; Eunice S Wang; Norbert Ifrah; Guy Gammon; Denise Trone; Deborah Lazzaretto; Mark Levis
Journal:  Lancet Oncol       Date:  2018-05-31       Impact factor: 41.316

3.  Inhibition of c-Kit by tyrosine kinase inhibitors.

Authors:  Allison Galanis; Mark Levis
Journal:  Haematologica       Date:  2014-11-25       Impact factor: 9.941

4.  Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor.

Authors:  Lauren Y Lee; Daniela Hernandez; Trivikram Rajkhowa; Samuel C Smith; Jayant Ranganathan Raman; Bao Nguyen; Donald Small; Mark Levis
Journal:  Blood       Date:  2016-12-01       Impact factor: 22.113

5.  Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML.

Authors:  Jorge E Cortes; Martin S Tallman; Gary J Schiller; Denise Trone; Guy Gammon; Stuart L Goldberg; Alexander E Perl; Jean-Pierre Marie; Giovanni Martinelli; Hagop M Kantarjian; Mark J Levis
Journal:  Blood       Date:  2018-06-06       Impact factor: 22.113

6.  Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML.

Authors:  Amy Sexauer; Alexander Perl; Xiaochuan Yang; Michael Borowitz; Christopher Gocke; Trivikram Rajkhowa; Christian Thiede; Mark Frattini; Grant E Nybakken; Keith Pratz; Judith Karp; B Douglas Smith; Mark Levis
Journal:  Blood       Date:  2012-09-25       Impact factor: 22.113

7.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

Authors:  Bruce D Cheson; John M Bennett; Kenneth J Kopecky; Thomas Büchner; Cheryl L Willman; Elihu H Estey; Charles A Schiffer; Hartmut Doehner; Martin S Tallman; T Andrew Lister; Francesco Lo-Coco; Roel Willemze; Andrea Biondi; Wolfgang Hiddemann; Richard A Larson; Bob Löwenberg; Miguel A Sanz; David R Head; Ryuzo Ohno; Clara D Bloomfield; Francesco LoCocco
Journal:  J Clin Oncol       Date:  2003-12-15       Impact factor: 44.544

8.  FLT3 inhibitor-induced neutrophilic dermatosis.

Authors:  Amir T Fathi; Long Le; Robert P Hasserjian; Hossein Sadrzadeh; Mark Levis; Yi-Bin Chen
Journal:  Blood       Date:  2013-05-17       Impact factor: 22.113

9.  Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.

Authors:  Michael D Amatangelo; Lynn Quek; Alan Shih; Eytan M Stein; Mikhail Roshal; Muriel D David; Benoit Marteyn; Noushin Rahnamay Farnoud; Stephane de Botton; Olivier A Bernard; Bin Wu; Katharine E Yen; Martin S Tallman; Elli Papaemmanuil; Virginie Penard-Lacronique; Anjan Thakurta; Paresh Vyas; Ross L Levine
Journal:  Blood       Date:  2017-06-06       Impact factor: 25.476

10.  Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.

Authors:  Alexander E Perl; Jessica K Altman; Jorge Cortes; Catherine Smith; Mark Litzow; Maria R Baer; David Claxton; Harry P Erba; Stan Gill; Stuart Goldberg; Joseph G Jurcic; Richard A Larson; Chaofeng Liu; Ellen Ritchie; Gary Schiller; Alexander I Spira; Stephen A Strickland; Raoul Tibes; Celalettin Ustun; Eunice S Wang; Robert Stuart; Christoph Röllig; Andreas Neubauer; Giovanni Martinelli; Erkut Bahceci; Mark Levis
Journal:  Lancet Oncol       Date:  2017-06-20       Impact factor: 41.316

View more
  21 in total

Review 1.  The genomics of acute myeloid leukemia in children.

Authors:  Shannon E Conneely; Rachel E Rau
Journal:  Cancer Metastasis Rev       Date:  2020-03       Impact factor: 9.264

2.  Erythroid differentiation of myeloblast induced by gilteritinib in relapsed FLT3-ITD-positive acute myeloid leukemia.

Authors:  Hyun Don Yun; Sunita Nathan; Melissa Larson; Mohammad J Hussain; Deborah A Katz; Ankur Varma; Ira Miller; Celalettin Ustun
Journal:  Blood Adv       Date:  2019-11-26

3.  Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML.

Authors:  Sung Choe; Hongfang Wang; Courtney D DiNardo; Eytan M Stein; Stéphane de Botton; Gail J Roboz; Jessica K Altman; Alice S Mims; Justin M Watts; Daniel A Pollyea; Amir T Fathi; Martin S Tallman; Hagop M Kantarjian; Richard M Stone; Lynn Quek; Zenon Konteatis; Lenny Dang; Brandon Nicolay; Parham Nejad; Guowen Liu; Vickie Zhang; Hua Liu; Meredith Goldwasser; Wei Liu; Kevin Marks; Chris Bowden; Scott A Biller; Eyal C Attar; Bin Wu
Journal:  Blood Adv       Date:  2020-05-12

4.  Gilteritinib Inhibits Glutamine Uptake and Utilization in FLT3-ITD-Positive AML.

Authors:  Megan E Zavorka Thomas; Xiyuan Lu; Zahra Talebi; Jae Yoon Jeon; Daelynn R Buelow; Alice A Gibson; Muhammad Erfan Uddin; Lindsey T Brinton; Julie Nguyen; Meghan Collins; Alessia Lodi; Shannon R Sweeney; Moray J Campbell; Douglas H Sweet; Alex Sparreboom; Rosa Lapalombella; Stefano Tiziani; Sharyn D Baker
Journal:  Mol Cancer Ther       Date:  2021-09-13       Impact factor: 6.261

5.  Cytarabine-induced differentiation of AML cells depends on Chk1 activation and shares the mechanism with inhibitors of DHODH and pyrimidine synthesis.

Authors:  Barbara Tomic; Tomislav Smoljo; Hrvoje Lalic; Vilma Dembitz; Josip Batinic; Drago Batinic; Antonio Bedalov; Dora Visnjic
Journal:  Sci Rep       Date:  2022-07-05       Impact factor: 4.996

Review 6.  Gilteritinib: potent targeting of FLT3 mutations in AML.

Authors:  Mark Levis; Alexander E Perl
Journal:  Blood Adv       Date:  2020-03-24

7.  A novel differentiation response with combination IDH inhibitor and intensive induction therapy for AML.

Authors:  Emily F Mason; Olga Pozdnyakova; Mikhail Roshal; Amir T Fathi; Eytan M Stein; P Brent Ferrell; Aaron C Shaver; Mark Frattini; Hongfang Wang; Lei Hua; Jimmy Mu; Sung Choe; Rengyi Xu; Caroline Almon; Michael Cooper; Richard M Stone; Robert P Hasserjian; Michael R Savona
Journal:  Blood Adv       Date:  2021-04-27

8.  The FLT3 Y842D mutation may be highly sensitive to midostaurin: a case report.

Authors:  Shujiao He; Minjie Zhang; Jieying Li; Weiqiang Zhao; Li Yu; Ying Han; Yanbin Pang
Journal:  J Int Med Res       Date:  2022-05       Impact factor: 1.573

9.  Selective Inhibition of JAK1 Primes STAT5-Driven Human Leukemia Cells for ATRA-Induced Differentiation.

Authors:  Haley E Ramsey; Kristy Stengel; James C Pino; Gretchen Johnston; Merrida Childress; Agnieszka E Gorska; Pia M Arrate; Londa Fuller; Matthew Villaume; Melissa A Fischer; P Brent Ferrell; Caroline E Roe; Jing Zou; Alexander L R Lubbock; Matthew Stubbs; Sandra Zinkel; Jonathan M Irish; Carlos F Lopez; Scott Hiebert; Michael R Savona
Journal:  Target Oncol       Date:  2021-07-29       Impact factor: 4.864

10.  GZD824 as a FLT3, FGFR1 and PDGFRα Inhibitor Against Leukemia In Vitro and In Vivo.

Authors:  Yuting Wang; Lenghe Zhang; Xia Tang; Jinfeng Luo; Zhengchao Tu; Kaili Jiang; Xiaomei Ren; Fang Xu; Shingpan Chan; Yuhua Li; Zhang Zhang; Ke Ding
Journal:  Transl Oncol       Date:  2020-04-01       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.